Karina Karina, Anggara Mahardika, Grady Krisandi, Imam Rosadi, Ratna Purwoko, Sarah Listyo Astuti, Diani Nazma, Louis Martin Christoffel, Meliana Siswanto, Johannes Albert Biben, Krista Ekaputri, Kuswan Ambar Pamungkas, Tommy P. Sibuea, Azza Maryam
{"title":"自体活化富血小板血浆辅助治疗孕妇特应性皮炎的疗效和安全性","authors":"Karina Karina, Anggara Mahardika, Grady Krisandi, Imam Rosadi, Ratna Purwoko, Sarah Listyo Astuti, Diani Nazma, Louis Martin Christoffel, Meliana Siswanto, Johannes Albert Biben, Krista Ekaputri, Kuswan Ambar Pamungkas, Tommy P. Sibuea, Azza Maryam","doi":"10.17532/jhsci.2023.2178","DOIUrl":null,"url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder which involves skin barrier and immune dysregulation. The management of AD involves the use of moisturizers and immunosuppressant which are only used for temporary symptom relief and may potentially harm the fetal growth. Autologous activated platelet-rich plasma (aaPRP) is a potential adjuvant treatment for symptom control in pregnant AD patient. This report examines a case of a pregnant patient with AD treated with aaPRP and the monitoring of fetal growth until birth. Case Report: A 37-year-old pregnant patient with a history of AD when in contact with latex or consumption of dairy products came to Hayandra Clinic. As she had been working as anesthesiologist continuously in contact with latex gloves, she underwent routine aaPRP therapy for 3 years and had 15 aaPRP treatments over the course of her pregnancy. The patient had lesser lesions when AD was induced, no exacerbation of symptoms during pregnancy, and the baby was healthy during pregnancy to birth. Conclusion: The use of aaPRP therapy for the management of AD may be indicated as it controls the symptoms yet is safe for the patient during pregnancy. There was also no harm effect showing on the fetal development. A larger study such as randomized controlled trial is required to evaluate our findings.","PeriodicalId":15927,"journal":{"name":"Journal of Health Sciences","volume":"65 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"The efficacy and safety of autologous activated platelet-rich plasma therapy as adjuvant treatment of atopic dermatitis in pregnant woman\",\"authors\":\"Karina Karina, Anggara Mahardika, Grady Krisandi, Imam Rosadi, Ratna Purwoko, Sarah Listyo Astuti, Diani Nazma, Louis Martin Christoffel, Meliana Siswanto, Johannes Albert Biben, Krista Ekaputri, Kuswan Ambar Pamungkas, Tommy P. Sibuea, Azza Maryam\",\"doi\":\"10.17532/jhsci.2023.2178\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder which involves skin barrier and immune dysregulation. The management of AD involves the use of moisturizers and immunosuppressant which are only used for temporary symptom relief and may potentially harm the fetal growth. Autologous activated platelet-rich plasma (aaPRP) is a potential adjuvant treatment for symptom control in pregnant AD patient. This report examines a case of a pregnant patient with AD treated with aaPRP and the monitoring of fetal growth until birth. Case Report: A 37-year-old pregnant patient with a history of AD when in contact with latex or consumption of dairy products came to Hayandra Clinic. As she had been working as anesthesiologist continuously in contact with latex gloves, she underwent routine aaPRP therapy for 3 years and had 15 aaPRP treatments over the course of her pregnancy. The patient had lesser lesions when AD was induced, no exacerbation of symptoms during pregnancy, and the baby was healthy during pregnancy to birth. Conclusion: The use of aaPRP therapy for the management of AD may be indicated as it controls the symptoms yet is safe for the patient during pregnancy. There was also no harm effect showing on the fetal development. A larger study such as randomized controlled trial is required to evaluate our findings.\",\"PeriodicalId\":15927,\"journal\":{\"name\":\"Journal of Health Sciences\",\"volume\":\"65 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-09-30\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.17532/jhsci.2023.2178\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Nursing\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17532/jhsci.2023.2178","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Nursing","Score":null,"Total":0}
The efficacy and safety of autologous activated platelet-rich plasma therapy as adjuvant treatment of atopic dermatitis in pregnant woman
Introduction: Atopic dermatitis (AD) is a chronic relapsing inflammatory skin disorder which involves skin barrier and immune dysregulation. The management of AD involves the use of moisturizers and immunosuppressant which are only used for temporary symptom relief and may potentially harm the fetal growth. Autologous activated platelet-rich plasma (aaPRP) is a potential adjuvant treatment for symptom control in pregnant AD patient. This report examines a case of a pregnant patient with AD treated with aaPRP and the monitoring of fetal growth until birth. Case Report: A 37-year-old pregnant patient with a history of AD when in contact with latex or consumption of dairy products came to Hayandra Clinic. As she had been working as anesthesiologist continuously in contact with latex gloves, she underwent routine aaPRP therapy for 3 years and had 15 aaPRP treatments over the course of her pregnancy. The patient had lesser lesions when AD was induced, no exacerbation of symptoms during pregnancy, and the baby was healthy during pregnancy to birth. Conclusion: The use of aaPRP therapy for the management of AD may be indicated as it controls the symptoms yet is safe for the patient during pregnancy. There was also no harm effect showing on the fetal development. A larger study such as randomized controlled trial is required to evaluate our findings.